Collaborative Arrangements (Tables)

6 Months Ended

Jun. 30, 2014

During the three and six months ended June 30, 2014 and 2013, the Company recognized the following revenues attributable to the CFFT collaboration:



	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2013		2014		2013
	(in thousands)
Collaborative revenues attributable to the CFFT collaboration	$	1,604	$	4,244	$	4,472	$	7,803

During the three and six months ended June 30, 2014 and 2013, the Company recognized the following revenues attributable to the Janssen NV collaboration:



	Three Months Ended June 30,				Six Months Ended June 30,
	2014		2013		2014		2013
	(in thousands)
Royalty revenues (INCIVO)	$	5,698	$	44,070	$	10,633	$	83,114
Collaborative revenues:
Up-front and amendment payments revenues	$	—	$	3,107	$	—	$	6,214
Net reimbursement for telaprevir development costs	1,483		37		2,872		9
Reimbursement for manufacturing services	—		—		—		10,299
Total collaborative revenues attributable to the Janssen NV collaboration	$	1,483	$	3,144	$	2,872	$	16,522
Total revenues attributable to the Janssen NV collaboration	$	7,181	$	47,214	$	13,505	$	99,636

Summary of activity related to net loss (income) attributable to noncontrolling interest (Alios)

A summary of net loss attributable to noncontrolling interest (Alios) for the three and six months ended June 30, 2013 is as follows:



	Three Months Ended June 30, 2013			Six Months Ended June 30, 2013
	(in thousands)
Loss before benefit from income taxes	$	6,824		$	12,121
Decrease in fair value of contingent milestone and royalty payments	80			2,820
Benefit from income taxes	(2,357		)	(5,783		)
Net loss attributable to noncontrolling interest (Alios)	$	4,547		$	9,158